Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma
Background/Aims: Hodgkin Lymphoma (HL) has become one of the most treatable cancers, with more than 80% patients in the advanced stage being cured through improvement of therapeutic regimens. Nevertheless, some treatments were accompanied with toxicities.Methods: In the current study, a network meta...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.694545/full |
| _version_ | 1818407507916226560 |
|---|---|
| author | Fajun Pei Yang Yu Yang Yu Bin Dong Hui Guan Xinzhe Dong Fen Zhao Fen Zhao |
| author_facet | Fajun Pei Yang Yu Yang Yu Bin Dong Hui Guan Xinzhe Dong Fen Zhao Fen Zhao |
| author_sort | Fajun Pei |
| collection | DOAJ |
| description | Background/Aims: Hodgkin Lymphoma (HL) has become one of the most treatable cancers, with more than 80% patients in the advanced stage being cured through improvement of therapeutic regimens. Nevertheless, some treatments were accompanied with toxicities.Methods: In the current study, a network meta-analysis (NMA) was conducted to compare the efficacies and toxicities of different chemotherapy regimens for advanced Hodgkin lymphoma (HL). We reviewed PubMed and EMBASE databases from inception to May 2018, and identified randomized controlled trials (RCTs) in which advanced HL patients received chemotherapy. Fourteen eligible RCTs published between 1992 and 2017 were enrolled in this NMA. These studies included a total of 5,964 HL patients, and assessed at least one of seven different chemotherapy regimens. Direct and indirect evidence was combined to calculate odds ratios (ORs) and 95% confidence intervals (95% CIs), and to establish a surface under the cumulative ranking (SUCRA) curve.Results: A cluster analysis was performed to evaluate efficacies and toxicities of different regimens. The COPP + ABVD (cyclophosphamide + vincristine + procarbazine + prednisone + doxorubicin + bleomycin + vinblastine + dacarbazine) regimen had the highest SUCRA partial response and overall remission rate values, while the ABVD regimen resulted in the lowest incidences of anemia, thrombocytopenia, neutropenia, and leucopenia.Conclusion: Cluster analysis revealed that COPP + ABVD had the best efficacy against advanced HL among the seven regimens, and ABVD had the lowest toxicity. |
| first_indexed | 2024-12-14T09:28:57Z |
| format | Article |
| id | doaj.art-bf77a664bda34765b159ad5a49981c0e |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-14T09:28:57Z |
| publishDate | 2021-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-bf77a664bda34765b159ad5a49981c0e2022-12-21T23:08:07ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-11-011210.3389/fphar.2021.694545694545Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin LymphomaFajun Pei0Yang Yu1Yang Yu2Bin Dong3Hui Guan4Xinzhe Dong5Fen Zhao6Fen Zhao7Department of Urology Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaSchool of Graduate Studies, Shandong Academy of Medical Sciences, Shandong First Medical University, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Medical Imaging, The First People’s Hospital of Pingdu, Qingdao, ChinaDepartment of Radiation Oncology, The Fourth People’s Hospital of Jinan, Jinan, ChinaDepartment of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, ChinaShandong University, Jinan, ChinaBackground/Aims: Hodgkin Lymphoma (HL) has become one of the most treatable cancers, with more than 80% patients in the advanced stage being cured through improvement of therapeutic regimens. Nevertheless, some treatments were accompanied with toxicities.Methods: In the current study, a network meta-analysis (NMA) was conducted to compare the efficacies and toxicities of different chemotherapy regimens for advanced Hodgkin lymphoma (HL). We reviewed PubMed and EMBASE databases from inception to May 2018, and identified randomized controlled trials (RCTs) in which advanced HL patients received chemotherapy. Fourteen eligible RCTs published between 1992 and 2017 were enrolled in this NMA. These studies included a total of 5,964 HL patients, and assessed at least one of seven different chemotherapy regimens. Direct and indirect evidence was combined to calculate odds ratios (ORs) and 95% confidence intervals (95% CIs), and to establish a surface under the cumulative ranking (SUCRA) curve.Results: A cluster analysis was performed to evaluate efficacies and toxicities of different regimens. The COPP + ABVD (cyclophosphamide + vincristine + procarbazine + prednisone + doxorubicin + bleomycin + vinblastine + dacarbazine) regimen had the highest SUCRA partial response and overall remission rate values, while the ABVD regimen resulted in the lowest incidences of anemia, thrombocytopenia, neutropenia, and leucopenia.Conclusion: Cluster analysis revealed that COPP + ABVD had the best efficacy against advanced HL among the seven regimens, and ABVD had the lowest toxicity.https://www.frontiersin.org/articles/10.3389/fphar.2021.694545/fullhodgkin lymphomachemotherapyefficacyrandomized controlled trialnetwork meta-analysis |
| spellingShingle | Fajun Pei Yang Yu Yang Yu Bin Dong Hui Guan Xinzhe Dong Fen Zhao Fen Zhao Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma Frontiers in Pharmacology hodgkin lymphoma chemotherapy efficacy randomized controlled trial network meta-analysis |
| title | Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma |
| title_full | Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma |
| title_fullStr | Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma |
| title_full_unstemmed | Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma |
| title_short | Efficacies and Toxicities of Seven Chemotherapy Regimens for Advanced Hodgkin Lymphoma |
| title_sort | efficacies and toxicities of seven chemotherapy regimens for advanced hodgkin lymphoma |
| topic | hodgkin lymphoma chemotherapy efficacy randomized controlled trial network meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.694545/full |
| work_keys_str_mv | AT fajunpei efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT yangyu efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT yangyu efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT bindong efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT huiguan efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT xinzhedong efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT fenzhao efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma AT fenzhao efficaciesandtoxicitiesofsevenchemotherapyregimensforadvancedhodgkinlymphoma |